Boston-based AI Proteins, a biotech that uses computational de novo protein design to create therapeutic miniproteins, has ...
Brexit by the ABPI, emphasizing the need for more resources and flexible licensing. The regulator faces challenges including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback